Get the Stockscreener App
7.06
3.98%
0.27
After Hours:
7.03
-0.03
-0.42%
Armata Pharmaceuticals Inc stock is traded at $7.06, with a volume of 33,647.
It is up +3.98% in the last 24 hours and down -12.30% over the past month.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections in the United States. The company develops its products using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains. The company is also developing and advancing synthetic phage for treating diseases caused by pseudomonas aeruginosa. Armata Pharmaceuticals, Inc. is headquartered in Marina del Rey, California.
See More
Previous Close:
$6.79
Open:
$6.91
24h Volume:
33,647
Relative Volume:
0.55
Market Cap:
$259.18M
Revenue:
$5.20M
Net Income/Loss:
$-282.61M
P/E Ratio:
-0.9093
EPS:
-7.764
Net Cash Flow:
$-24.47M
1W Performance:
-6.61%
1M Performance:
-12.30%
6M Performance:
+24.73%
1Y Performance:
+279.57%
1-Day Range:
$6.76
$7.15
1-Week Range:
$6.3701
$8.045
52-Week Range:
$1.75
$16.34
Armata Pharmaceuticals Inc Stock (ARMP) Company Profile
Name
Armata Pharmaceuticals Inc
Sector
Industry
Phone
310-655-2928
Address
4503 Glencoe Avenue, Marina del Rey, CA
Compare ARMP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARMP
Armata Pharmaceuticals Inc
|
7.06 | 253.67M | 5.20M | -282.61M | -24.47M | -7.764 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Armata Pharmaceuticals Inc Stock (ARMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-19-19 | Initiated | Ladenburg Thalmann | Buy |
Armata Pharmaceuticals Inc Stock (ARMP) Latest News
Armata Pharmaceuticals (ARMP) Edges Lower Amid Sector Pressure – Key Levels in FocusPost-Earnings Moves - newsline.com
ARMATA PHARMACEUTICALS INC (ARMP) Stock Chart - ChartMill
Armata Pharmaceuticals (ARMP) Slips 3.6% as Stock Tests Key Support LevelsPCR Mean Reversion - newsline.com
Armata Pharmaceuticals Slips 2.47% as Bears Test Support Near $7.12Mid Cap Momentum - newsline.com
Armata Pharmaceuticals (ARMP) Climbs 3.62% – Testing Key Resistance Near $8.26Fibonacci Arc - newsline.com
Armata Pharmaceuticals Inc. (ARMP) Q1 2026 Earnings: Significant Earnings Miss Reflects Pre-Revenue Development StageEarnings Cycle Report - newsline.com
Armata Pharmaceuticals (ARMP) price target increased by 16.67% to 17.85 - MSN
Armata Pharmaceuticals (ARMP) Shows Modest Uptick as Stock Holds Above Key SupportRectangle Pattern - The Legal Advocate
Armata Pharmaceuticals Q1 2026 Earnings: Deep EPS Miss Masks Strategic Progress, Stock RisesProfitability Analysis - newsline.com
Armata Pharmaceuticals (ARMP) Q1 2026 Earnings: Massive EPS Miss as Pre-Revenue Biotech Struggles with Costs - newsline.com
Armata Pharmaceuticals Q1 2026 Earnings: Significant EPS Miss but Stock Rises on Pipeline ProgressFinal Results - Newser
Why Is Armata Pharmaceuticals, Inc. (ARMP) Stock Down Today? - Meyka
Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update - GuruFocus
Armata Pharmaceuticals 1Q Loss/Shr $3.16 >ARMP - Moomoo
H.C. Wainwright Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $15 - Moomoo
ARMP: Armata Reports Increased Revenue and Focuses on Phase 3 Tr - GuruFocus
Armata Pharmaceuticals (ARMP) Q1 2026: EPS -3.16 Misses Est. -0. - GuruFocus
Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update - TradingView
Armata Secures New Loan Amid Wider Quarterly Loss - TipRanks
Armata Pharmaceuticals (ARMP) now 82.7% owned by Innoviva after new loan - Stock Titan
Armata Pharmaceuticals, Inc. 1Q 2026: Revenue $789K, EPS ($3.16) — 10-Q Summary - TradingView
Armata (NYSE: ARMP) loss, debt surge and Phase 3 bacteremia trial plan - Stock Titan
Armata Pharma Entered Into Secured Credit Agreement With Innoviva for $25 M Maturing in 2029 >ARMP - Moomoo
Press Release: Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update - Moomoo
ARMP Technical Analysis | Trend, Signals & Chart Patterns | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
JonesTrading Maintains Armata Pharmaceuticals(ARMP.US) With Buy Rating, Maintains Target Price $20 - Moomoo
FDA grants fast track status to Armata’s bacterial infection drug By Investing.com - Investing.com India
Armata Gains FDA Fast Track for AP-SA02 Therapy - TipRanks
FDA grants fast track status to Armata’s bacterial infection drug - Investing.com India
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02 - PR Newswire
MSN Money - MSN
The industry tailwinds powering Armata (ARMP) growth (Underperforming) 2026-05-05Continuation Signals - newser.com
Study maps phage in Armata’s treatment candidate for lung infections - Stock Titan
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology" - marketscreener.com
ARMP Forecast, Price Target & Analyst Ratings | ARMATA PHARMACEUTICALS INC (NYSEARCA:ARMP) - ChartMill
Armata Pharmaceuticals (ARMP) director receives 51,280 stock options at $12.92 - Stock Titan
Director Daniel Gilmer reported as insider at Armata Pharmaceuticals (ARMP) - Stock Titan
Armata Pharmaceuticals : 2026 Annual Meeting Proxy - marketscreener.com
[ARS] Armata Pharmaceuticals, Inc. SEC Filing - Stock Titan
Armata Pharmaceuticals (NASDAQ: ARMP) 2026 proxy details pay, control and going concern risk - Stock Titan
Pfizer Inc. (PFE)Senior Commercial Leader Daniel B. Gilmer, Ph.D. Appointed to Armata Pharmaceuticals Board of DirectorsCertified Trade Ideas - newser.com
Armata Pharmaceuticals Appoints Pfizer Executive Daniel B. Gilmer, Ph.D. to Board to Advance Bacteriophage Therapeutics Commercialization 1 - Minichart
Armata Pharmaceuticals Adds Pfizer Executive to Board of Directors - TipRanks
Armata Pharmaceuticals adds Pfizer executive to board - Investing.com
Arm appoints Dr. Daniel Gilmer to Board effective April 24, 2026 - TradingView
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors – Company AnnouncementFT.com - Financial Times
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
ARMP (Armata Pharmaceuticals Inc.) Q4 2025 EPS drastically misses analyst estimates, sending its shares down 6.37% today.Geographic Trends - Xã Thanh Hà
ARMP (Armata Pharmaceuticals Inc.) falls 5.64% as drastically wider than expected Q4 2025 net loss spooks investors.Retail Trader Ideas - UBND thành phố Hải Phòng
Armata Pharmaceuticals Inc Stock (ARMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):